Drug intelligence / Profile preview

CTH522 + aluminum hydroxide

Development stage: Unknown
Lead developer: Statens Serum Institut
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

CTH522 + aluminum hydroxide is a vaccine candidate for the prevention of Chlamydia trachomatis infections. It consists of CTH522, a recombinant chimeric protein containing portions of the C. trachomatis major outer membrane protein (MOMP), adjuvanted with aluminum hydroxide. The CTH522 component combines a partial sequence of MOMP from serovar D with external domains from serovars E, F, and G, representing the most prevalent Chlamydia serovars.

Other names: CTH522/AlOH

Targets

BCR (Immunoglobulin G B Cell Receptor)

Beyond the preview

Go deeper on CTH522 + aluminum hydroxide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTH522 + aluminum hydroxide.

Explore the full profile